Medical Malpractice in Uveitis: A Review of Clinical Entities and Outcomes

Reddy, Ashvini K.; Engelhard, Stephanie B; Shah, Christopher T.; Sim, Austin J.; Thorne, Jennifer E.

doi:10.1080/09273948.2016.1202289

Cited by 15 publications

(23 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…WestLaw®, however, is a database of settlements and verdicts from a variety of insurers, which may present a more global picture of litigation in ophthalmology. As we have stated in other reports [11,12], potential limitations include changes in clinical practice over time, including new technology allowing more precise diagnosis and management, and changing patient and physician demographics and cultural values. Additionally, WestLaw® does not include out-of-court settlements and dropped cases, and it has been said that up to 85% of cases never make it to trial [35].…”

Section: Discussionmentioning

confidence: 99%

“…As described in previous publications [11,12], the database was queried to search all US civil trials involving ophthalmologists using the search terms “ophthalmology” or “ophthalmologist” and “malpractice” anywhere in the retrieved documents. Exclusion criteria included (1) ophthalmologist named as expert witness but not defendant and (2) filings before January 1, 1930, or after December 31, 2014.…”

Section: Methodsmentioning

confidence: 99%

“…Several publications focus on litigation in ophthalmology [11,12,13,14,15,16,17,18]; however, there is no study focused specifically on ocular oncology in the literature to our knowledge. Ocular oncology represents a wide range of diseases involving not only the eye itself, but also the orbit and adnexal structures.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Malpractice Litigation in Ocular Oncology

et al. 2017

Self Cite

View full text Add to dashboard Cite

Aims: The aim of this study was to report and analyze the causes and outcomes of ocular oncology malpractice litigation. Methods: The WestLaw® database was reviewed for all litigation related to ophthalmology in the United States from 1930 to 2014. All ocular oncology cases were included in this analysis and compared to other ophthalmic subspecialties. Results: Sixteen ocular oncology malpractice cases were included in this study. Overall, 56.3% of the cases were resolved in favor of the defendant. A total of 62.5% of cases were resolved via jury verdict, with 30.0% resulting in plaintiff verdicts with mean adjusted awards of USD 511,244.48, comparable to ophthalmology as a whole. Three cases (18.8%) resulted in settlements with mean adjusted indemnities of USD 828,928.14. A total of 87.5% of cases alleged insufficient intervention resulting in loss of vision and/or death. The most common clinical entities were uveal melanoma (31.3%), retinoblastoma (12.5%), and sebaceous cell carcinoma (12.5%). Conclusions: Ocular oncology malpractice litigation was relatively rare and outcomes generally favored defendants; however, unlike other subspecialties in ophthalmology, blindness or premature death were common to all cases, highlighting both the importance of prompt diagnosis and treatment and the difficulty inherent in diagnosing ocular malignancies.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Malpractice Litigation in Ocular Oncology

et al. 2017

Self Cite

View full text Add to dashboard Cite

show abstract

“…Intraocular inflammatory disease is a primary cause of vision loss in industrialized countries . Uveitis, a common inflammatory ocular disease, may encompass the anterior and posterior segments of the eye (eg iris, ciliary body and choroid).…”

Section: Introductionmentioning

confidence: 99%

SARI prevents ocular angiogenesis and inflammation in mice

Zhang

Dai

et al. 2020

J Cellular Molecular Medi

View full text Add to dashboard Cite

SARI (Suppressor of AP-1, regulated by IFN-β) is known to play an important role in some systemic disease processes such an inflammatory conditions and cancer. We hypothesize that SARI may also play a role in ocular diseases involving inflammation and neovascularization. To explore our hypothesis, further, we investigated an endotoxin-induced uveitis (EIU) and experimental argon laser-induced choroidal neovascularization (CNV) model in SARI wild-type (SARI WT ) and SARI-deficient (SARI −/− ) mice. Through imaging, morphological and immunohistochemical (IHC) studies, we found that SARI deficiency exacerbated the growth of CNV. More VEGF-positive cells were presented in the retina of SARI −/− mice with CNV. Compared to SARI WT mice, more inflammatory cells infiltrated the ocular anterior segment and posterior segments in SARI −/− mice with EIU. Collectively, the results point to a potential dual functional role of SARI in inflammatory ocular diseases, suggesting that SARI could be a potential therapy target for ocular inflammation and neovascularization. K E Y W O R D Sage-related macular degeneration, choroidal neovascularization, regulated by IFN-β, Suppressor of AP-1, Uveitis, vascular endothelial growth factor

show abstract

“…Anatomically, the eyeball can be divided into two segments: the anterior segment, which is composed of the cornea, aqueous humor, conjunctiva, iris, and lens; and the posterior segment, which is composed of the retina–choroid, sclera, the optic nerve, and vitreous humor ( Figure 1 ). Each segment is susceptible to either inherited or contracted disorders, and the most commonly encountered disorders, including cataracts, glaucoma, diabetic retinopathy, and uveitis, cause significant visual impairment and loss . To treat these ocular diseases, therapeutic agents must be delivered to the targeted ocular tissue.…”

Section: Introductionmentioning

confidence: 99%

Stimulus‐Responsive Hydrogel for Ophthalmic Drug Delivery

Lin

Lei

Shi

et al. 2019

Macromolecular Bioscience

View full text Add to dashboard Cite

Blindness and vision impairment are major global health problems. Effective ophthalmic drug delivery poses a significant challenge because of protective physiological barriers and various biological clearance mechanisms that result in extremely low ocular bioavailability. Over the past several decades, several safe and effective ophthalmic drug delivery approaches have been promoted to combat these problems and to improve ocular bioavailability. Among these approaches, the stimulus‐responsive hydrogel for topical drug delivery has gained increasing attention because of its prolonged drug retention at the local site and enhanced ocular bioavailability. This review summarizes and presents recent advances and perspectives of a stimulus‐responsive hydrogel for ophthalmic drug delivery.

show abstract

Medical Malpractice in Uveitis: A Review of Clinical Entities and Outcomes

Cited by 15 publications

References 15 publications

Malpractice Litigation in Ocular Oncology

Malpractice Litigation in Ocular Oncology

SARI prevents ocular angiogenesis and inflammation in mice

Stimulus‐Responsive Hydrogel for Ophthalmic Drug Delivery

Contact Info

Product

Resources

About